(Total Views: 582)
Posted On: 05/15/2020 1:02:26 PM
Post# of 154002
Absolutely correct.
Sorrento has yet to even begin to test on people.
Mean while, Cytodyn and our drug Leronlimab is proving effective in a number of areas on live, breathing people.
We are light years ahead of them in testing and positive results for people in poor health, or in ANY sort of health for that matter.
The press and market reaction does demonstrate the difference in our being an OTC stock vs Sorrento on NASDAQ. NP and team has so much going on and uplifting has to be on their agenda, but I can't help but think difference we experience on NASDAQ or NYSE would be astounding. As an investor, the share price should go thru the roof. For the company, the press coverage and exposure should bring all sorts of help and assistance to bring Leronlimab to the public.
Sorrento has yet to even begin to test on people.
Mean while, Cytodyn and our drug Leronlimab is proving effective in a number of areas on live, breathing people.
We are light years ahead of them in testing and positive results for people in poor health, or in ANY sort of health for that matter.
The press and market reaction does demonstrate the difference in our being an OTC stock vs Sorrento on NASDAQ. NP and team has so much going on and uplifting has to be on their agenda, but I can't help but think difference we experience on NASDAQ or NYSE would be astounding. As an investor, the share price should go thru the roof. For the company, the press coverage and exposure should bring all sorts of help and assistance to bring Leronlimab to the public.
(2)
(0)
